Literature DB >> 3278366

Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin.

R Gotthard1, G Bodemar, U Brodin, K A Jönsson.   

Abstract

Patients with dyspepsia of unknown origin were randomly allocated to a controlled double-blind study to examine the symptomatic effect of cimetidine and antacid especially on the relief of pain, nausea, and bloating. Two hundred and twenty-two patients with no previous history of peptic ulcer disease and no evidence of other organic causes of dyspepsia were treated for 6 weeks with placebo, cimetidine, or antacid. The results showed that cimetidine was superior to both placebo and antacid in relieving pain and nausea but not bloating. Certain background factors, such as epigastric pain and symptoms relieved by solid food, had a significant positive influence on the outcome of treatment. When the impact of background factors was taken into account, cimetidine was found to be more effective than both placebo and antacid also with regard to the number of patients who improved in general well-being.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3278366     DOI: 10.3109/00365528809093840

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  15 in total

Review 1.  Review article: current treatment options and management of functional dyspepsia.

Authors:  B E Lacy; N J Talley; G R Locke; E P Bouras; J K DiBaise; H B El-Serag; B P Abraham; C W Howden; P Moayyedi; C Prather
Journal:  Aliment Pharmacol Ther       Date:  2012-05-16       Impact factor: 8.171

2.  Economic costs of functional dyspepsia.

Authors:  O Nyrén; G Lindberg; E Lindström; R Seensalu
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

3.  An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group.

Authors:  S J Veldhuyzen van Zanten; N Flook; N Chiba; D Armstrong; A Barkun; M Bradette; A Thomson; F Bursey; P Blackshaw; D Frail; P Sinclair
Journal:  CMAJ       Date:  2000-06-13       Impact factor: 8.262

4.  Treatment of functional dyspepsia.

Authors:  Smita L S Halder; Nicholas J Talley
Journal:  Curr Treat Options Gastroenterol       Date:  2005-08

5.  Habit, prejudice, power and politics: issues in the conversion of H2-receptor antagonists to over-the-counter use.

Authors:  R H Hunt
Journal:  CMAJ       Date:  1996-01-01       Impact factor: 8.262

Review 6.  Management of dyspepsia in general practice. A critical assessment.

Authors:  C Tosetti; V Stanghellini
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

7.  Functional Dyspepsia: A New Rome III Paradigm.

Authors:  Smita L S Halder; Nicholas J Talley
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

8.  Long term acid suppressing treatment in general practice.

Authors:  S D Ryder; S O'Reilly; R J Miller; J Ross; M R Jacyna; A J Levi
Journal:  BMJ       Date:  1994-03-26

Review 9.  Functional dyspepsia. Current treatment recommendations.

Authors:  Gerald Holtmann; Nicholas J Talley
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

10.  Antacid (A02A) and antiulcer (A02B) drug prescription patterns: predicting factors, dosage and treatment duration.

Authors:  M M Morales Suárez-Varela; M A Pérez-Benajas; V J Girbes Pelechano; A Llopis-González
Journal:  Eur J Epidemiol       Date:  1998-06       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.